Need a specific person's email?
Browse PHARNEXT's employee directory (about 19 employees) and reveal verified emails free.
PHARNEXT's most common email format is FLast@pharnext.com (ex. JDoe@pharnext.com), used for 79% of pharnext.com addresses. PHARNEXT uses 4 email patterns.
| Format | Example | Share of pharnext.com |
|---|---|---|
| FLast@pharnext.comMost common | JDoe@pharnext.com | |
| First.Last@pharnext.com | John.Doe@pharnext.com | |
| First@pharnext.com | John@pharnext.com | |
| FirstMiddle.Last@pharnext.com | JohnMichael.Doe@pharnext.com |
Browse PHARNEXT's employee directory (about 19 employees) and reveal verified emails free.
Biotechnology ResearchÎle-de-France, France11-50 Employees
Pharnext is a biotechnology company focused on developing therapeutics for neurodegenerative diseases where curative or disease-modifying options are lacking. Its lead program PXT3003 targets Charcot–Marie–Tooth disease type 1A and has completed an international Phase III trial with favorable topline results, and it holds orphan drug status in Europe and the United States. A pivotal Phase III study in CMT1A, named PREMIER, is currently under way, while a second lead asset, PXT864, has shown encouraging Phase II results in Alzheimer's disease and is expected to advance through partnerships. Pharnext operates in the biotechnology research sector from Suresnes, near Paris, France, and is listed on the Euronext Growth market. Its work originates from Pleotherapy, the company's R&D approach, and targets patients with neurodegenerative conditions where current treatment options remain limited.
Most common format
FLast@pharnext.com
Example: JDoe@pharnext.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.